The regulatory disturbance is more of a sentiment shock; UBS expects limited financial impact for China pharmacy chains

Overview

This report discusses the market reaction in China’s pharmaceutical retail sector following the NHSA’s regulatory talks and news of tighter oversight of in-store GLP-1 sales at offline pharmacies. The National Healthcare Security Administration recently summoned the responsible persons of pharmacy chains such as Laobaixing, Yangtianhe, Yifeng, and Henan Zhang Zhongjing, asking them to correct improper use of medical insurance funds, assign responsibility, conduct compliance training, and improve internal control systems. After the announcement, shares of the listed pharmacy chains covered by UBS fell about 4-8% by midday. UBS’s core view is that the event is a short-term hit to market sentiment, but because the number of stores involved and the amounts of improper funds are small, the financial impact on listed companies is expected to be limited.

Core views

UBS believes that negative news about pharmacy compliance is not unusual, and past incidents disclosed by local or provincial medical insurance authorities have typically resulted in relatively small penalties, with limited financial impact on listed pharmacy chains. This event may cause a short-term hit to stock prices and sentiment, but listed pharmacy chains generally already have relatively strong internal control systems that can reduce the risk of large-scale violations. As industry regulation tightens and smaller stores are weeded out, listed chains with scale, compliance, and management capabilities may instead benefit from market consolidation. UBS continues to favor Yifeng and Dashenlin, believing both companies are trading at historical valuation lows and are likely to speed up store expansion during the year, driving earnings upside and gradual re-rating.

Analysis framework

The report combines event-driven analysis with industry fundamentals: it first assesses the direct impact of the NHSA’s regulatory talks on listed chains, then uses company feedback, historical comparable incidents, channel checks, annual report information, and valuation levels to judge short-term sentiment and medium- to long-term investment value. UBS values Yifeng and Dashenlin using DCF and also references their 2026E PE multiples versus global pharmacy peers.

Methodology notes

• Valuation methodDCF

  discounted cash flow valuation

  UBS uses DCF to derive target prices for Yifeng and Dashenlin, focusing on future cash flows, expansion pace, profit margins, and discount-rate assumptions.

• Relative valuationPE valuation comparison

  2026E PE

  The report notes that Yifeng and Dashenlin are both trading at about 14x 2026E PE, near historical lows and at a discount to global pharmacy peers.

• Event impact assessmentRegulatory event analysis

  separate assessment of regulatory talk's financial and sentiment impact

  The report separates the short-term market-sentiment shock from the actual financial impact of the regulatory talk, arguing that the stock reaction may be negative, but the stores and amounts involved are small and the financial impact is limited.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Yifeng

  A listed pharmacy chain covered by UBS and rated Buy

  Strengths

  Trading at a historical valuation low, large store footprint, relatively mature internal control system, and likely to expand amid industry store closures.

  Weaknesses

  The large store base means compliance issues can still arise at franchise and terminal execution levels.

  Comparison

  It trades at a valuation discount to global pharmacy peers; relative to non-listed or regional pharmacies, its compliance and management systems are stronger.

  Risks

  Medical insurance policy adjustments, regulatory penalties, cross-regional expansion competition, and diversion to online pharmacies.

• Dashenlin

  A listed pharmacy chain covered by UBS and rated Buy

  Strengths

  Trading at about 14x 2026E PE, near historical lows, with a clear beneficiary story from industry consolidation.

  Weaknesses

  The industry's margins and customer traffic are highly sensitive to medical insurance payment policies.

  Comparison

  Like Yifeng, it is one of UBS's preferred large pharmacy chains, valued using DCF and viewed as having re-rating potential.

  Risks

  Medical insurance reimbursement scope and pricing policy, requirements for licensed pharmacists and classification management, regional leader competition, and migration to online channels.

• China pharmaceutical retail sector

  The core sector covered by this report

  Strengths

  Tighter regulation can raise industry compliance standards, and top chains may benefit from consolidation.

  Weaknesses

  The sector is highly sensitive to medical insurance policy, offline foot traffic, and the regulatory environment.

  Comparison

  Top listed chains have scale, internal-control, and compliance advantages over fragmented pharmacies.

  Risks

  Stricter oversight of medical insurance funds, sales restrictions on categories such as GLP-1, low-price competition from pharmaceutical e-commerce, and migration of offline traffic.

Key data

• Regulatory talk date2026-05-16The NHSA announced recent talks with executives of relevant pharmacy chains.
• Report date2026-05-18UBS Global Research publication date.
• Short-term stock reactionDown 4-8%The intraday share-price decline of UBS-covered listed pharmacy chains after the news.
• Laobaixing affected stores6 storesThe company said the affected scope was small.
• Yifeng affected stores1 franchise storeThe company said the amount of improper funds was very small.
• Yifeng/Laobaixing store scaleNearly 15,000 stores eachThe large store network makes it difficult to fully avoid compliance risks.
• Yifeng and Dashenlin valuationAbout 14x 2026E PENear historical lows and at a discount to global pharmacy peers.

Impact & implications

In the short term, tighter regulation of medical insurance fund usage and news of stricter oversight of in-store GLP-1 sales may continue to weigh on risk appetite for pharmacy chains, especially when market sentiment is fragile and stock-price volatility is amplified. Over the medium to long term, stronger regulation can help standardize industry order, raise compliance thresholds, and speed the exit of weaker and non-compliant stores; if top listed chains can maintain high compliance standards, they may gain expansion opportunities from industry consolidation and help regulators reduce the oversight burden of fragmented store networks.

Risks

• Changes in medical insurance policy, especially reimbursement scope and reimbursement prices for products sold through pharmacy channels, may affect pharmacy foot traffic and margins.
• If pharmacies violate regulatory rules, they may face severe consequences such as loss of eligibility for medical insurance reimbursement or revocation of operating licenses.
• As industry consolidation accelerates, regional leaders may hinder cross-regional expansion by chains, and large chains may also compete directly with one another.
• Pharmaceutical e-commerce prices are usually lower than offline pharmacies, and changes in patient purchasing habits could shift some offline traffic online.
• Regulatory news may continue to suppress short-term market sentiment and delay valuation recovery.

What to watch

• Whether the NHSA imposes further penalties on the relevant pharmacy chains or discloses remediation progress.
• Whether regulation of in-store GLP-1 sales in Shanghai and other regions tightens further.
• The store expansion, franchise management, and compliance training execution of Yifeng, Dashenlin, and Laobaixing.
• Whether the pace of store closures in the industry accelerates and whether top chains can capture market share.
• Whether 2026E earnings estimates are revised up and whether low valuations lead to gradual re-rating.